A $1,000 investment in Halozyme Therapeutics made in September 2016 would be worth $10,866.33 as of September 1, 2026, representing a 986.63% gain. The biopharmaceutical company's success is driven by its ENHANZE drug delivery technology licensed to major pharma partners like Roche, Takeda, J&J, and AbbVie, generating royalties that comprise over 55% of revenues. While strong demand for partnered drugs and new collaboration deals support growth, biosimilar competition for blockbuster drugs and dependence on partner revenues present risks.

Pfizer's oncology revenues rose 3% to $4.17 billion in Q2 2026, with Padcev sales climbing 23% to $667 million following FDA approval for muscle-invasive bladder cancer. The company is advancing multiple pipeline candidates, including PF-08634404 in nine studies, and aims to have eight or more blockbuster oncology medicines by 2030. Pfizer trades at an attractive valuation with a Zacks Rank #3 (Hold) rating.

The global palmoplantar pustulosis market is experiencing steady growth driven by increased awareness, diagnosis rates, and development of targeted biologic therapies. Key advances in IL-23 and IL-36 research, precision medicine, and AI-assisted diagnostics are accelerating treatment development. While topical therapies remain central for mild cases, systemic agents and biologics are supporting moderate-to-severe disease management. Growth is reinforced by clinical trials and regulatory approvals across North America, Europe, and Asia-Pacific, though high treatment costs and limited access in developing regions remain challenges.

Revolution Medicines received rapid FDA approval for Rasonque, a novel pancreatic cancer treatment using a RAS inhibitor mechanism. The drug demonstrated strong Phase 3 trial results and analysts project peak annual sales of $11.5 billion. The stock has surged 178% year-to-date, with potential for further expansion into other cancer indications affecting 30% of solid tumors.

Johnson & Johnson is highlighted as an excellent dividend stock choice due to its 64-year streak of consecutive annual dividend increases, making it a Dividend King. With a diversified portfolio spanning Innovative Medicine and MedTech segments, 28 billion-dollar product platforms, and strategic investments in oncology, immunology, and robotic surgery, J&J offers stable, growing cash payouts backed by a resilient healthcare business. The company raised 2026 guidance and continues to innovate while maintaining a ~2% dividend yield.

Johnson & Johnson stands out as an attractive dividend stock due to its diversified healthcare business, strong financial health with an AAA credit rating, impressive 64-year dividend increase streak, and recent progress in resolving talc-related lawsuits. Despite patent cliffs and drug price negotiations, the company expects 6.8% revenue growth for fiscal 2026, demonstrating resilience.

The global atrial fibrillation treatment devices market is expected to grow at a 13.1% CAGR from $9.6 billion in 2026 to $29 billion by 2035, driven by aging populations, rising AF prevalence affecting 50-60 million people worldwide, and increasing adoption of advanced ablation and left atrial appendage closure technologies. Pulsed field ablation is forecast to generate over 60% of market revenue by 2035, while North America will retain approximately 50% of global market share. Asia-Pacific is expected to register the fastest regional growth.

The global Intravascular Lithotripsy (IVL) market is projected to grow from USD 1.01 billion in 2025 to USD 4.19 billion by 2035, expanding at a 15.3% CAGR. Growth is driven by increasing prevalence of calcified coronary and peripheral artery disease, adoption of minimally invasive procedures, and expanding peripheral IVL applications. North America leads with 58% market share, while Asia-Pacific is the fastest-growing region.

BCC Research's mid-year assessment highlights AI-driven discovery, precision oncology, and connected health as major growth themes in the life sciences sector. Key opportunities include smart inhalers with AI integration, genomic profiling platforms, cardiovascular drug innovations, and in vitro toxicity testing. The sector benefits from aging populations, regulatory support for non-animal testing, and emerging market expansion, though risks include patent expirations and reimbursement variability.

Parabilis Medicines announced the appointment of Craig L. Tendler, M.D., an accomplished oncology drug development leader with over 30 years of experience and two decades at Johnson & Johnson, to its Board of Directors. Dr. Tendler will continue his role as scientific advisor while joining the board to support the company's advancement of zolucatetide across multiple indications and its broader pipeline of Helicon therapeutics.

American States Water (AWR) has extended its dividend growth streak to 72 consecutive years with an 8.2% increase, making it one of fewer than 60 companies with 50+ years of annual dividend increases. The regulated water and electric utility operates in California and manages military base facilities, generating stable cash flows. With a 2.5% yield, 8.7% compound annual dividend growth over the past decade, and a target of 7%+ future growth, the company remains an underrecognized dividend growth stock.

Johnson & Johnson and AbbVie are recommended as long-term dividend stocks to hold indefinitely. Both are Dividend Kings with strong cash flows, reliable dividend payments, and solid historical returns. JNJ has increased dividends for 64 consecutive years with a 1.96% yield, while ABBV has 54 years of increases with a higher 2.6% yield and stronger recent performance.